Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
Overview
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is a clinical-stage pharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing significant unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases.
Reviva uses a chemical genomics driven technology platform and proprietary chemistry to develop new medicines. Reviva’s pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house.
Recent
Events
Investor Contacts
Company
Narayan Prabhu, CFO
Reviva Pharmaceuticals
Phone: 408.501.8881
Email: [email protected]
Investor Relations
Lytham Partners, LLC
Phone: 602.889.9700
Email: [email protected]
Transfer Agent
Continental Stock Transfer & Trust
1 State Street, 30th Floor
New York, NY 10004-1561
Phone: 212.509.4000
Email: [email protected]
Website: https://continentalstock.com/